No Picture
Trading Ideas

Moderna’s COVID-19 Vaccine’s Pricing Disappoints Investors, But This Analyst Remains With the Bulls

mRNA vaccine maker Moderna (MRNA) has undoubtably been one of 2020’s success stories. One of the frontrunners in the race to develop a COVID-19 vaccine, investors have cheered each step of its candidate’s progress. While shares haven’t soared as majestically as those by some of its smaller sized peers, they have nevertheless appreciated by 243% so far this year.Yet, the company sparked confusion among investors last week after announcing that the US government has put an order in for 100 million doses of the company’s COVID-19 vaccine candidate mRNA-1273, for a total cost of $1.53 billion. As it turns out, …read more […]

No Picture
Trading Ideas

Why a Bad Valuation Can Ruin a Great Company

Shopify (NYSE: SHOP) is one of the hottest stocks on the market.
Just check out this stock chart…

A $10,000 investment in Shopify five years ago is now worth more than $280,000! And the vast majority of that increase came this year.
No question… I wish that I had bought shares of this company a few years ago. But would I buy shares today?
No way.
Even when compared with some of the most expensive stocks in the world, Shopify is outrageously overpriced.
Founded more than 10 years ago when entrepreneur Tobias Lütke wanted to sell snowboards, Shopify is a great company… but at today’s valuation, …read more […]

No Picture
Trading Ideas

New Study May Provide Insights Into Novavax’s COVID-19 Vaccine; Top Analyst Weighs In

This week kicked off with a bang, as Novavax (NVAX) took another step forward in the COVID-19 vaccine race. On Monday August 17, the biotech announced the start of the Phase 2b trial of NVX-CoV2373, its adjuvanted recombinant protein COVID-19 vaccine candidate, in South Africa.The trial is part of a randomized, observer-blinded, placebo-controlled efficacy study and is comprised of two cohorts. Cohort 1 will assess the candidate’s efficacy, safety and immunogenicity in approximately 2,665 healthy volunteers, while the second will evaluate the vaccine in 240 medically stable, HIV-positive adult patients.5-star analyst Mayank Mamtani, of B.Riley FBR, points out that the …read more […]

No Picture
Trading Ideas

These 2 Beaten-Down Stocks Are Poised to Bounce Back, Say Analysts

Down doesn’t mean out. When a stock takes a tumble, investors sometimes jump the gun and assume that the name has reached the end of the line. Sure, a significant share price decline should sound the alarm bells, as it could indicate underlying problems with the business or insurmountable headwinds.However, there’s another side to the story. These falls could reflect temporary challenges that can ultimately be overcome, with the lower prices presenting an opportunity to get in on the action before the stock takes back off on an upward trajectory.So, how are investors supposed to distinguish between the names poised …read more […]

No Picture
Trading Ideas

AI Is Booming: Here Are 3 Stocks Analysts Are Betting On

Artificial Intelligence isn’t just science fiction anymore. The technology is maturing, and AI is allowing machines to take an ever-growing role is more and more sectors of our digital world. Financial services, healthcare, manufacturing, and retail all are being transformed – to varying degrees, and as varying paces – by AI applications.In retail, AI tech is transforming inventory systems, making it easier for employees to track stock from the backrooms to the shelves. Office environments are changing, too, as AI has smoothed over the transition to mass work-from-home by easing IT support systems. Perhaps the greatest changes are coming in …read more […]